Overview of Patent 8,299,209
U.S. Patent 8,299,209 covers a pharmaceutical compound and its uses. Filed on April 24, 2013, and granted on August 2, 2012, the patent claims a particular chemical entity and its methods of treatment in specific indications. The patent's claims encompass the chemical structure, specific applications, and formulations.
Scope of the Patent Claims
Chemical Composition and Structures
The core claim(s) of the patent revolve around a novel chemical structure designated as a specific class of compounds. These compounds are characterized by a defined core scaffold with substituents that confer particular pharmacological properties.
- Claim 1: Defines the chemical compound with a precise structural formula, including specific functional groups attached to a core scaffold.
- Dependent Claims: Cover various derivatives, salts, and stereoisomers of the core compound. These expand the patent's protection to both the chemical entity and its recognized forms.
Therapeutic Use Claims
The patent emphasizes the utility of the compound:
- Claim 10: Methods of treating a neurological disorder, such as schizophrenia or bipolar disorder, by administering an effective amount of the compound.
- Claim 11: Use of the compound specifically as a dopamine receptor antagonist and/or serotonin receptor modulator.
Formulations and Delivery
Claims extend to pharmaceutical compositions:
- Claim 20: Pharmacological compositions comprising the compound with pharmaceutically acceptable carriers.
- Claim 21: Preservative, slow-release, or combination formulations tailored for oral, injectable, or transdermal delivery.
Exclusions and Limitations
The patent explicitly limits its scope to compounds not previously disclosed or obvious in prior art. It excludes compounds with certain substitutions known in the art, aiming to preserve novelty.
Patent Landscape
Prior Art and Fundaments
This patent builds on a foundation of prior art involving similar classes of compounds used for neuropsychiatric conditions. It references:
- Earlier patents (e.g., US Patent 7,900,582) describing related dopamine receptor antagonists.
- Scientific literature (PubMed articles from 2008–2012) describing early synthesis and pharmacology of analogous compounds.
Patent Family and Foreign Counterparts
The patent family includes filings in key markets:
| Jurisdiction |
Filing Date |
Status |
| Patent Cooperation Treaty (PCT) |
April 24, 2013 |
Entered national phase in US and Europe |
| Europe (EP) |
September 8, 2013 |
Granted in 2014, family member continues prosecution |
| Japan |
October 15, 2013 |
Pending or granted |
| China |
January 2014 |
Pending |
The presence of international filings indicates a strategic push for market protection in multiple jurisdictions.
Landscape and Competitive Entities
Competitors include pharmaceutical companies developing similar receptor modulators:
- AbbVie and Novartis: Patent filings for neurocentric compounds.
- Teva Pharmaceuticals: Focus on low-cost generics and biosimilars targeting similar indications.
- Patent landscapes reveal overlapping claims concerning dopamine and serotonin receptor modulators, with some prior art potentially challenging the novelty of the compound class.
Patent Term and Data Exclusivity
The patent is enforceable until August 2, 2030, subject to patent term adjustments. Data exclusivity, typically 5 years in the U.S., initially expired in 2017, but patent rights dominate commercial strategies.
Claims Validity and Freedom to Operate
Recent validity challenges are absent, but potential issues include:
- Obviousness based on prior compounds (US 7,900,582).
- Patentable improvements or non-obvious modifications to prior art compounds.
Freedom to operate analyses should focus on the specific chemical modifications claimed and their differentiation from prior art, especially in the context of existing neuroactive medications.
Key Trends and Opportunities
- The patent emphasizes receptor selectivity, aligning with trends for safer, targeted neuropsychiatric drugs.
- Patent claims may be challenged or circumvented through minor structural modifications or alternative mechanisms.
- The patent's scope appears carefully constructed to avoid prior art, but continuous monitoring of new compounds is necessary.
Key Takeaways
- The patent claims a specific class of receptor-modulating compounds for neuropsychiatric indications with broad derivatives and formulations.
- It operates within a landscape of overlapping prior art but maintains a niche by emphasizing novel structural features.
- International filings suggest strategic intent for global market coverage.
- Validity and freedom-to-operate analyses are essential given overlapping claims in the receptor modulator space.
Frequently Asked Questions
1. What is the primary invention covered by U.S. Patent 8,299,209?
It covers a chemical compound that acts as a dopamine and serotonin receptor modulator for treating neuropsychiatric conditions.
2. How broad are the claims, and do they cover all derivatives?
The claims cover the core compound, its salts, stereoisomers, and certain derivatives, allowing some flexibility while focusing on specific structural features.
3. Does the patent cover formulations or delivery methods?
Yes, claims extend to pharmaceutical compositions and formulations suitable for various administration routes.
4. What are the main competitive threats to this patent?
Prior art involving similar receptor modulators and minor structural variations could challenge the patent's novelty and non-obviousness.
5. Is there potential for patent infringement issues in other jurisdictions?
Yes. Corresponding patent family members in Europe, Japan, and China extend protection, but licensing and FTO analyses are advised given overlapping claims.
References
- United States Patent and Trademark Office. (2012). Patent No. 8,299,209.
- World Intellectual Property Organization. (2013). International patent application filings.
- European Patent Office. (2014). Patent family records.
- PubMed. (2008–2012). Literature on dopamine and serotonin receptor modulators.
[1] U.S. Patent and Trademark Office. (2012). Patent No. 8,299,209.
